Use of Immunotherapy for Treatment of HIV Infections

Z. I. Berdiyeva^{1, 2}, P. E. Ignatov³, I. Kh. Mamatkulov² and M.P. Ignatov^3,

¹Republican Center for Combating AIDS, Tashkent, Republic of Uzbekistan, 12 Farkhod Street, Chilanzar - 16, 100135, Tashkent, Republic of Uzbekistan

²Research Institute for Epidemiology, Microbiology and Infectious Diseases, Ministry of Health of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan, Zakovat Str #2, 100133, Tashkent, Republic of Uzbekistan Uzbekistan

³IDEA Charity Foundation, Lake Elsinore, California, USA, PO BOX 804, 500 W Graham Ave, Lake Elsinore, CA, 92530

Cite this paper:
Z. I. Berdiyeva, P. E. Ignatov, I. Kh. Mamatkulov and M.P. Ignatov. Use of Immunotherapy for Treatment of HIV Infections. American Journal of Medical Sciences and Medicine. 2019; 7(2):36-38. doi: 10.12691/ajmsm-7-2-3

Abstract

This paper describes the comparative use of antiretroviral therapy both with and without immunotherapy. A unique immunocorrector called IMMUN-5 was used in conjunction with standard ART. The results presented in the table that follows shows that during the 6 months of complex therapy, the viral load in patients in the experimental groups fell by several hundreds of thousands while simultaneously the number of CD4 cells increased during treatment. The authors suggest that it may be possible to achieve long-term remission in all patients. This will eliminate a link in the epidemic chain as the reservoir of infection, and this will create guidelines for the development of global programs to effectively combat the AIDS epidemic.

Keywords:
AIDS immunotherapy remission cd4 lymphocytes viral load ART

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Kaufmann G. R., Perrin L., Pantaleo G., Opravil M., Furrer H., Telenti A. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-95.
[2]	Abrescia N. et. al. “Hepatotoxicity of Antiretroviral Drugs”. Curr. Pharm. Des, 2005;11(28): 3697-710.
[3]	Chen WT, Shiu CS, Yang JP, Simoni JM, Fredriksen-Goldsen KI, Lee TS, Zhao H. “Antiretroviral Therapy (ART) Side Effect Impacted on Quality of Life, and Depressive Symptomatology: A Mixed-Method Study” J AIDS Clin Res. 2013 Jun 29; 4: 218.
[4]	Dalakas, M. C. (2001), Peripheral neuropathy and antiretroviral drugs. Journal of the Peripheral Nervous System, 6: 14-20.
[5]	Arts, Eric J, and Daria J Hazuda. “HIV-1 antiretroviral drug therapy.” Cold Spring Harbor perspectives in medicine vol. 2,4 (2012): a007161.
[6]	Dalgleish, Angus. (1993). Immunotherapy of AIDS. Current opinion in biotechnology. 3. 650-5.
[7]	Hynes B., Burton D.. Developing an HIV Vaccine // Science 2017 17 Mar 2017 Vol. 355, Issue 6330, pp. 1129-1130.